Licochalcone B

Licochalcone B is an extract from the root of Glycyrrhiza uralensis . Licochalcone B inhibits amyloid β ( 42 ) self-aggregation ( IC 50 =2.16 μM) and disaggregate pre-formed Aβ 42 fibrils, reduce metal-induced Aβ 42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction In Vitro Licochalcone B (IC 50 : 2.16 μM) inhibits self-mediated Aβ42 aggregation and disaggregates Aβ42 pre-formed fibrils. Licochalcone B (0-12 μM, 48 h) reduces the ROS generation and protects cells from H 2 O 2 -induced cell death in SH-SY5Y cells. Licochalcone B (10 μM, 1 h) inhibits LPS-induced NF-κB activation in RAW264.7 cells. Licochalcone B (10 μM, 1 h) inhibits the LPS-induced phosphorylation of NF-κB p65 at serine 276, and inhibited the expression of TNFα and MCP-1. Licochalcone B (0-20 μM, 24 or 48 h) inhibits human NSCLC cell growth. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: RAW264.7 cells Concentration: 10 µM Incubation Time: 1 h Result: Inhibited the phosphorylation of NF-κB at serine 276 but not at serine 536. In Vivo Licochalcone B (1-25 mg/kg, oral gavage) alleviates oxidative stress of hepatotoxicity in mice induced by CCl 4. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice induced by CCl 4Dosage: 1, 5, 25 mg/kg Administration: Oral gavage. Result: Elevated the levels of SOD and GSH, and reduced the GSSG levels. Form:Solid IC50& Target:NLRP3

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet